GHP Investment Advisors Inc. grew its position in shares of Petmed Express Inc (NASDAQ:PETS) by 29.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 51,652 shares of the company’s stock after buying an additional 11,656 shares during the quarter. GHP Investment Advisors Inc. owned 0.25% of Petmed Express worth $2,350,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also recently bought and sold shares of PETS. Sei Investments Co. grew its holdings in shares of Petmed Express by 50,142.9% during the third quarter. Sei Investments Co. now owns 3,517 shares of the company’s stock valued at $117,000 after buying an additional 3,510 shares during the last quarter. LS Investment Advisors LLC grew its holdings in shares of Petmed Express by 283.5% during the fourth quarter. LS Investment Advisors LLC now owns 2,861 shares of the company’s stock valued at $130,000 after buying an additional 2,115 shares during the last quarter. Sterling Investment Advisors Ltd. grew its holdings in shares of Petmed Express by 118.5% during the fourth quarter. Sterling Investment Advisors Ltd. now owns 2,950 shares of the company’s stock valued at $134,000 after buying an additional 1,600 shares during the last quarter. Thompson Siegel & Walmsley LLC purchased a new stake in shares of Petmed Express during the third quarter valued at approximately $149,000. Finally, CenterStar Asset Management LLC purchased a new stake in shares of Petmed Express during the fourth quarter valued at approximately $169,000. Hedge funds and other institutional investors own 91.30% of the company’s stock.
In related news, CEO Menderes Akdag sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $51.00, for a total value of $1,530,000.00. Following the sale, the chief executive officer now owns 490,000 shares in the company, valued at $24,990,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gian Fulgoni sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $44.38, for a total transaction of $887,600.00. Following the completion of the sale, the director now owns 55,900 shares in the company, valued at approximately $2,480,842. The disclosure for this sale can be found here. Insiders sold 65,000 shares of company stock worth $3,229,500 in the last 90 days. 4.00% of the stock is currently owned by corporate insiders.
Petmed Express (NASDAQ:PETS) last issued its earnings results on Monday, January 22nd. The company reported $0.44 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.33 by $0.11. Petmed Express had a net margin of 12.84% and a return on equity of 34.04%. The company had revenue of $60.10 million for the quarter, compared to analysts’ expectations of $56.76 million. During the same quarter last year, the company posted $0.24 earnings per share. The firm’s quarterly revenue was up 13.6% on a year-over-year basis. analysts forecast that Petmed Express Inc will post 1.77 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, February 16th. Investors of record on Monday, February 5th were issued a $0.25 dividend. The ex-dividend date of this dividend was Friday, February 2nd. This represents a $1.00 annualized dividend and a yield of 2.14%. This is a boost from Petmed Express’s previous quarterly dividend of $0.20. Petmed Express’s dividend payout ratio (DPR) is currently 59.17%.
A number of equities research analysts have recently commented on PETS shares. BidaskClub upgraded shares of Petmed Express from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 9th. Northcoast Research set a $58.00 price target on shares of Petmed Express and gave the company a “buy” rating in a report on Wednesday, January 3rd. Finally, ValuEngine upgraded shares of Petmed Express from a “hold” rating to a “buy” rating in a report on Wednesday, February 7th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $42.80.
ILLEGAL ACTIVITY WARNING: This article was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.americanbankingnews.com/2018/03/14/petmed-express-inc-pets-stake-raised-by-ghp-investment-advisors-inc.html.
Petmed Express Company Profile
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Want to see what other hedge funds are holding PETS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Petmed Express Inc (NASDAQ:PETS).
Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.